Chinese Real-world Study of Treatment of Vestibular Migraine

Summary

Vestibular migraine is a phenotype of migraine, characterized by more prominent vertigo symptoms compared to headache. Treatments for VM are mainly divided into two categories: acute treatment and preventive treatment. Acute treatment aims to reduce the severity and duration of a single episode, while preventive treatment aims to decrease the frequency, severity, and duration of attacks. Current acute treatments are primarily divided into pain relief and anti-dizziness, with specific drugs such as triptans and ergots being applicable for pain relief, but only betahistine has weak evidence for anti-dizziness, and relevant clinical evidence is very scarce. Preventive treatment mainly refers to migraine preventive treatments, with recommended medications including traditional drugs like topiramate, flunarizine, propranolol, etc., but the efficacy and safety of these drugs are limited. CGRP-targeted drugs are believed to play a role in the preventive treatment of VM, and there are related literature reports, but most are small-sample studies or retrospective studies. This study aims to explore the real-world efficacy of CGRP-targeted drugs in the acute and preventive treatment of VM through a prospective real-world study.

Conditions

• Vestibular Migraine
• Dizziness
• Vertigo

Interventions

DRUG

CGRP R Inhibitor; CGRP Inhibitor

Participants who are prescribed CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A1.Participants who are prescribed CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B1.

DRUG

none-CGRP

Participants who are prescribed none-CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A2.Participants who are prescribed none-CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B2.

Sponsors & Collaborators

• First People's Hospital of Hangzhou

  collaborator OTHER

• Sir Run Run Shaw Hospital

  collaborator OTHER

• Affiliated Hospital of Jiaxing University

  collaborator OTHER

• The People's Hospital of Quzhou

  collaborator OTHER

• The First People Hospital of Hangzhou Lin An District

  collaborator UNKNOWN

• Shaoxing People's Hospital

  collaborator OTHER

• Jiaxing Hospital of T.C.M

  collaborator UNKNOWN

• Hangzhou Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Affiliated Wenling Hospital of Wenzhou Medical University

  collaborator OTHER

• First Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Second Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Zhongshan Hospital Of Traditional Chinese Medicine

  collaborator OTHER

• The First People's Hospital of Huzhou

  collaborator OTHER

• Xin Hua Hospital of Zhejiang Province

  collaborator OTHER

• The Affiliated Hospital of Hangzhou Normal University

  collaborator OTHER

• Huzhou Central Hospital

  collaborator OTHER

• Chinese Medical University

  collaborator UNKNOWN

• Tiantai People Hospital

  collaborator UNKNOWN

• Zhejiang University

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  lead OTHER

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-12-31

Primary Completion

2027-12-31

Completion

2028-12-31

FDA Drug

Yes